The DOI matches its Crossref record.
Acetylation of prostaglandin synthase by aspirin.
Open accessAbstract
When microsomes of sheep or bovine seminal vesicles are incubated with [acetyl-3H]aspirin (acetyl salicylic acid), 200 Ci/mol, we observe acetylation of a single protein, as measured by sodium dodecyl sulfate/polyacrylamide gel electrophoresis. The protein has a molecular weight of 85,000 and corresponds to a similar acetylated protein found in the particulate fraction of aspirin-treated human platelets. The aspirin-mediated acetylation reaction proceeds with the same time course and at the same concentration as does the inhibition of prostaglandin synthase (cyclo-oxygenase) (EC 1.14.99.1; 8,11,14-eicosatrienoate, hydrogen-donor:oxygen oxidoreductase) by the drug. At 100 muM aspirin, 50% inhibition of prostaglandin synthase and 50% of maximal acetylation are observed after 15 min at 37 degrees. Furthermore, the substrate for cyclo-oxygenase, arachidonic acid, inhibits protein acetylation by aspirin at concentrations (50% inhibition at 10-30 muM) which correlate with the Michaelis constant of arachidonic acid as a substrate for cyclooxygenase. Arachidonic acid analogues and indomethacin inhibit the acetylation reaction in proportion to their effectiveness as cyclo-oxygenase inhibitors. The results suggest that aspirin acts as an active-site acetylating agent for the enzyme cyclo-oxygenase. This action of aspirin may account for its anti-inflammatory and anti-platelet action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J., & Vane, J. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11693 · Cited by 1,659
Prostaglandin E2 synthesis and secretion: The role of PGE2 synthases
Park, J. Y., Pillinger, M. H., & Abramson, S. B. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.01.016 · Cited by 793
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review
Campbell, C. L., Smyth, S., Montalescot, G., & Steinhubl, S. R. (2007) · JAMA · doi:10.1001/jama.297.18.2018 · Cited by 444
COX-2: A Molecular Target for Colorectal Cancer Prevention
Brown, J. R., & DuBois, R. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.051 · Cited by 444
Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
AMP-activated protein kinase: maintaining energy homeostasis at the cellular and whole-body levels
Hardie, D. G. (2014) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071812-161148 · Cited by 281
Covalent Inhibition in Drug Discovery
Ghosh, A. K., Samanta, I., Mondal, A., & Liu, W. R. (2019) · ChemMedChem · doi:10.1002/cmdc.201900107 · Cited by 265
Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls
Kumalo, H., Bhakat, S., & Soliman, M. (2015) · Molecules · doi:10.3390/molecules20021984 · Cited by 158
Nonnarcotic Analgesic Use and the Risk of Hypertension in US Women
Dedier, J., Stampfer, M. J., Hankinson, S. E., Willett, W. C., Speizer, F. E., & Curhan, G. C. (2002) · Hypertension · doi:10.1161/01.hyp.0000035856.77718.da · Cited by 145
Beyond cysteine: recent developments in the area of targeted covalent inhibition
Mukherjee, H., & Grimster, N. P. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.011 · Cited by 95
Relevance of new drug discovery to reduce NF-κB activation in cardiovascular disease
Madonna, R., & De Caterina, R. (2012) · Vascular Pharmacology · doi:10.1016/j.vph.2012.02.005 · Cited by 46
Covalent fragment inhibits intramembrane proteolysis
Eden, A., Zhao, J., Xiao, Y., Gibson, J., & Wang, C. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.958399 · Cited by 3
Metadata
- Authors
- Roth, G. J., Stanford, N., & Majerus, P. W.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1975-08
- Volume
- 72
- Issue
- 8
- Pages
- 3073-3076
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1983759759
- Cited by
- 1,009
- References
- 0
- FWCI
- 23.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.